vs
AtriCure, Inc.（ATRC）とBRC Group Holdings, Inc.（RILY）の財務データ比較。上の社名をクリックして会社を切り替えられます
BRC Group Holdings, Inc.の直近四半期売上が大きい（$188.3M vs $140.5M、AtriCure, Inc.の約1.3倍）。AtriCure, Inc.の前年同期比売上増加率が高い（13.1% vs -21.9%）。過去8四半期でAtriCure, Inc.の売上複合成長率が高い（13.6% vs -15.4%）
AtriCure社は心房細動および関連する心臓疾患の治療向けの革新的な手術用ツール・治療ソリューションを研究開発・製造するグローバルな医療機器企業です。主に北米、欧州、アジア太平洋地域の病院、心臓外科センター、医療機関を顧客とし、低侵襲心臓手術を支援する製品を提供しています。
ATRC vs RILY — 直接比較
売上が大きい
RILY
1.3倍大きい
$140.5M
売上成長率が高い
ATRC
+34.9%の差
-21.9%
2年売上CAGRが高い
ATRC
2年複合成長率
-15.4%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $140.5M | $188.3M |
| 純利益 | — | $90.3M |
| 粗利率 | 75.0% | 79.5% |
| 営業利益率 | 1.8% | 32.3% |
| 純利益率 | — | 47.9% |
| 売上前年比 | 13.1% | -21.9% |
| 純利益前年比 | — | 1710.8% |
| EPS（希薄化後） | $0.04 | $2.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上ATRCRILY
| Q4 25 | $140.5M | $188.3M | ||
| Q3 25 | $134.3M | $215.3M | ||
| Q2 25 | $136.1M | $188.2M | ||
| Q1 25 | $123.6M | $197.2M | ||
| Q4 24 | $124.3M | $241.0M | ||
| Q3 24 | $115.9M | $225.5M | ||
| Q2 24 | $116.3M | $256.0M | ||
| Q1 24 | $108.9M | $263.4M |
純利益ATRCRILY
| Q4 25 | — | $90.3M | ||
| Q3 25 | $-267.0K | $91.1M | ||
| Q2 25 | $-6.2M | $139.5M | ||
| Q1 25 | $-6.7M | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $-7.9M | $-284.4M | ||
| Q2 24 | $-8.0M | $-433.6M | ||
| Q1 24 | $-13.3M | $-49.2M |
粗利率ATRCRILY
| Q4 25 | 75.0% | 79.5% | ||
| Q3 25 | 75.5% | 83.7% | ||
| Q2 25 | 74.5% | 81.3% | ||
| Q1 25 | 74.9% | 81.4% | ||
| Q4 24 | 74.5% | 79.8% | ||
| Q3 24 | 74.9% | 82.1% | ||
| Q2 24 | 74.7% | 84.5% | ||
| Q1 24 | 74.7% | 85.3% |
営業利益率ATRCRILY
| Q4 25 | 1.8% | 32.3% | ||
| Q3 25 | 0.2% | 30.4% | ||
| Q2 25 | -4.5% | 5.7% | ||
| Q1 25 | -4.8% | -31.2% | ||
| Q4 24 | -11.7% | -69.2% | ||
| Q3 24 | -6.4% | -36.4% | ||
| Q2 24 | -6.2% | -90.8% | ||
| Q1 24 | -10.0% | -6.1% |
純利益率ATRCRILY
| Q4 25 | — | 47.9% | ||
| Q3 25 | -0.2% | 42.3% | ||
| Q2 25 | -4.5% | 74.1% | ||
| Q1 25 | -5.5% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -6.8% | -126.1% | ||
| Q2 24 | -6.9% | -169.4% | ||
| Q1 24 | -12.2% | -18.7% |
EPS（希薄化後）ATRCRILY
| Q4 25 | $0.04 | $2.78 | ||
| Q3 25 | $-0.01 | $2.91 | ||
| Q2 25 | $-0.13 | $4.50 | ||
| Q1 25 | $-0.14 | $-0.39 | ||
| Q4 24 | $-0.33 | $-0.01 | ||
| Q3 24 | $-0.17 | $-9.39 | ||
| Q2 24 | $-0.17 | $-14.35 | ||
| Q1 24 | $-0.28 | $-1.71 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $167.4M | $226.6M |
| 総負債低いほど良い | — | $1.4B |
| 株主資本純資産 | $491.9M | $-171.5M |
| 総資産 | $654.2M | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資ATRCRILY
| Q4 25 | $167.4M | $226.6M | ||
| Q3 25 | $147.9M | $184.2M | ||
| Q2 25 | $117.8M | $267.4M | ||
| Q1 25 | $99.9M | $138.3M | ||
| Q4 24 | $122.7M | $146.9M | ||
| Q3 24 | $130.3M | $159.2M | ||
| Q2 24 | $114.0M | $236.9M | ||
| Q1 24 | $106.0M | $190.7M |
総負債ATRCRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | $61.9M | $1.3B | ||
| Q2 25 | $61.9M | $1.3B | ||
| Q1 25 | $61.9M | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $61.9M | — | ||
| Q1 24 | $61.9M | — |
株主資本ATRCRILY
| Q4 25 | $491.9M | $-171.5M | ||
| Q3 25 | $476.5M | $-260.5M | ||
| Q2 25 | $464.5M | $-351.7M | ||
| Q1 25 | $454.6M | $-496.8M | ||
| Q4 24 | $461.0M | $-488.2M | ||
| Q3 24 | $465.0M | $-497.6M | ||
| Q2 24 | $462.1M | $-218.3M | ||
| Q1 24 | $456.3M | $228.4M |
総資産ATRCRILY
| Q4 25 | $654.2M | $1.7B | ||
| Q3 25 | $635.4M | $1.7B | ||
| Q2 25 | $608.8M | $1.5B | ||
| Q1 25 | $591.6M | $1.5B | ||
| Q4 24 | $609.3M | $1.8B | ||
| Q3 24 | $615.1M | $2.2B | ||
| Q2 24 | $597.3M | $3.2B | ||
| Q1 24 | $591.6M | $5.0B |
負債/資本比率ATRCRILY
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $20.0M | $26.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $18.4M | — |
| FCFマージンFCF / 売上 | 13.1% | — |
| 設備投資強度設備投資 / 売上 | 1.1% | — |
| キャッシュ転換率営業CF / 純利益 | — | 0.29× |
| 直近12ヶ月FCF直近4四半期 | $48.3M | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローATRCRILY
| Q4 25 | $20.0M | $26.2M | ||
| Q3 25 | $26.7M | $-60.6M | ||
| Q2 25 | $21.6M | $-25.6M | ||
| Q1 25 | $-11.0M | $184.0K | ||
| Q4 24 | $5.8M | $-2.7M | ||
| Q3 24 | $20.0M | $19.5M | ||
| Q2 24 | $7.4M | $111.5M | ||
| Q1 24 | $-21.0M | $135.4M |
フリーキャッシュフローATRCRILY
| Q4 25 | $18.4M | — | ||
| Q3 25 | $24.1M | — | ||
| Q2 25 | $19.0M | — | ||
| Q1 25 | $-13.2M | — | ||
| Q4 24 | $3.1M | — | ||
| Q3 24 | $16.4M | — | ||
| Q2 24 | $5.0M | — | ||
| Q1 24 | $-23.8M | — |
FCFマージンATRCRILY
| Q4 25 | 13.1% | — | ||
| Q3 25 | 18.0% | — | ||
| Q2 25 | 13.9% | — | ||
| Q1 25 | -10.7% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 14.1% | — | ||
| Q2 24 | 4.3% | — | ||
| Q1 24 | -21.9% | — |
設備投資強度ATRCRILY
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.9% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 2.2% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | 2.5% | — |
キャッシュ転換率ATRCRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ATRC
| Appendage Management | $45.5M | 32% |
| Openheart | $38.5M | 27% |
| Other | $26.2M | 19% |
| Pain Management | $22.6M | 16% |
| Minimally Invasive | $7.7M | 6% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
